Physician profile
Robert E Satty
NPI 1295892347
$4,373.50
in general payments reported to CMS, 2019-2025
25 companies · $813 in 2025
The $813 reported for 2025 was more than what 88% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $189 · 2020: $136 · 2021: $704 · 2022: $468 · 2023: $943 · 2024: $1,120 · 2025: $813.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,876.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,875.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $889.98 | 2019-2025 | Cequa |
| Biotissue Holdings INC. | $544.50 | 2021-2025 | |
| Abbvie INC. | $433.93 | 2022-2025 | Durysta, Alphagan P, Vuity |
| Alcon Vision LLC | $381.00 | 2020-2025 | Tryptyr, Rocklatan, Eysuvis |
| Oyster Point Pharma, INC. | $334.50 | 2022-2025 | Tyrvaya, Ryzumvi |
| Bausch & Lomb Americas INC. | $320.76 | 2022-2025 | Miebo, Xiidra, Envista Mx60 Iol |
| Johnson & Johnson Vision Care, INC. | $245.62 | 2019-2025 | Acuvue |
| Tarsus Pharmaceuticals, INC. | $201.07 | 2024-2025 | Xdemvy |
| Allergan, INC. | $150.77 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $115.79 | 2019-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $98.57 | 2021 | |
| Kala Pharmaceuticals, INC. | $95.38 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $72.88 | 2019-2021 | |
| Harrow Eye, LLC | $70.62 | 2024-2025 | Vevye |
| Dompe US, INC. | $70.14 | 2024-2025 | Oxervate |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $65.34 | 2024-2025 | Iyuzeh |
| Coopervision INC. | $63.01 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $55.17 | 2019-2021 | |
| Carl Zeiss Meditec, INC. | $34.48 | 2020 | |
| Eyevance Pharmaceuticals LLC | $28.68 | 2020-2022 | |
| Glaukos Corporation | $28.54 | 2023 | Istent Inject Trabecular Micro-Bypass System Model G2-M-Is |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Rxsight INC | $19.32 | 2023 | Rxsight Contact Lens, Rxsight Light Adjustable Lens (Rxlal), Rxsight Injector Handpiece |
| Amgen INC. | $19.20 | 2024 | Tepezza |
| Eyepoint US, INC. | $14.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Satty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.